**AUTHOR CORRECTION** 



## Author Correction to: The effectiveness and safety of bevacizumab versus cetuximab in the treatment of colorectal cancer: a systematic review and meta-analysis

Yuying Cui<sup>1</sup> · Yingxue Guo<sup>2</sup>

Published online: 9 June 2023 © Springer Nature Switzerland AG 2023

## Author Correction: International Journal of Clinical Pharmacy (2022) 44:843–851 https://doi.org/10.1007/s11096-022-01415-6

In the original publication of the article, "TARE3" is corrected as "TRAE3-5" throughout the article.

In the introduction section, the sentence "with demonstrated benefits in overall survival" is removed and "with demonstrated benefits in overall survival in patients after complete resection of CRC metastases" is included.

The sentence "studies used bevacizumab containing regimen as an intervention group and cetuximab-containing regimen as a control group;" is removed and "studies that compared bevacizumab containing regimens and cetuximabcontaining regimens" is included.

The sentence "consulting with a third reviewer" is changed to "discussion".

The sub-section "Overall survival" is corrected as below,

A total of 8 studies reported OS [4, 15–20, 22]. The results of the meta-analysis showed that bevacizumab-containing regimens were significantly associated with longer OS than cetuximab-containing regimens in patients with CRC (HR 0.90, 95% CI 0.82 to 0.99, P < 0.0001, Fig. 3A). Similarly, the subgroup analysis of observational cohort studies showed a significantly longer OS in the bevacizumab-containing regimens (HR, 0.73, 95% CI 0.57–0.92, P = 0.008, Fig. 3A). However, the subgroup analysis of

The original article can be found online at https://doi.org/10.1007/s11096-022-01415-6.

<sup>1</sup> School of Clinical Medicine, Jiamusi University, Jiamusi 154007, China

<sup>2</sup> College of Pharmacy, Jiamusi University, Jiamusi 154007, Heilongjiang, China RCTs did not show significant differences in OS between the two regimens (HR 0.94, 95% CI 0.85–1.05, P=0.28, Fig. 3A). There was no difference between the above subgroups ( $P_{interaction} = 0.05$ ). There was significant heterogeneity between the studies (I2=65%) (Fig. 3A). There was no publication bias.

The sub section "Progression-free survival" is corrected as below,


We included a total of 8 studies that reported PFS [4, 15–21]. The results of the meta analysis found no significant differences in PFS between the bevacizumab-containing regimens and the cetuximab-containing regimens (HR 0.96, 95% CI 0.91 to 1.02, P=0.14, Fig. 3B). We found a difference in PFS between bevacizumab-containing regimens and cetuximab-containing regimens in the subgroup analysis of RCTs (HR 0.91, 95% CI 0.83–1.00, P=0.05, Fig. 3B) but not in the subgroup analysis of observational cohort studies (HR 0.99, 95% CI 0.92–1.06, P=0.82, Fig. 3B). Furthermore, there were no significant differences between RCTs and observational cohort studies ( $P_{interaction} = 0.14$ ). There was significant heterogeneity between the (I2 53.2%) (Fig. 3B) but no publication bias (Supplemental Fig. 1B).

In the discussion section, the sentence "The subgroup analysis of RCTs did not show significant differences in OS between the bevacizumab and cetuximab-containing regimens." is included.

The correct Fig. 3 is given below,

The original article has been corrected.

<sup>☑</sup> Yingxue Guo 13634544334@163.com



## в

-					Hazard Ratio	Hazard Ratio
_	Study or Subgroup	log[Hazard Ratio]	SE	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% CI
	1.2.1 RCT					
	Bennouna, J. 2018	-0.3425	0.1789	2.6%	0.71 [0.50, 1.01]	
	Cremolini, C. 2018	-0.3147	0.2356	1.5%	0.73 [0.46, 1.16]	
	Heinemann, V. 2014	-0.0619	0.0887	10.6%	0.94 [0.79, 1.12]	
	Nishizawa, Y. 2021	-0.5798	0.3537	0.7%	0.56 [0.28, 1.12]	
	Venook, A.P. 2017	-0.0513	0.0628	21.1%	0.95 [0.84, 1.07]	
	Subtotal (95% CI)			36.4%	0.91 [0.83, 1.00]	•
	Heterogeneity: Chi <sup>2</sup> = 5.29, df = 4 (P = 0.26); l <sup>2</sup> = 24%					
	Test for overall effect: Z	= 2.00 (P = 0.05)				
	1.2.2 OC \$					
	Bai, L. 2016	0.1398	0.1365	4.5%	1.15 [0.88, 1.50]	
	Houts, A.C. 2017	0.2776	0.1954	2.2%	1.32 [0.90, 1.94]	
	Yang, Y.H. 2014	-0.0305	0.0382	57.0%	0.97 [0.90, 1.05]	
	Subtotal (95% CI)			63.6%	0.99 [0.92, 1.06]	•
	Heterogeneity: Chi <sup>2</sup> = 3.66, df = 2 (P = 0.16); l <sup>2</sup> = 45%					
	Test for overall effect: Z	= 0.22 (P = 0.82)				
	Tetel (OFW CI)			400.0%	0.00 10.04 4.023	
	Total (95% CI)				0.96 [0.91, 1.02]	· · · · · · · · · · · · · · · · ·
Heterogeneity: Chi <sup>2</sup> = 11.08, df = 7 (P = 0.14); l <sup>2</sup> = 37%					0.5 0.7 1 1.5 2	
	Test for overall effect: Z			-		Favours [experimental] Favours [control]
	Test for subaroup differences: Chi <sup>2</sup> = 2.14. df = 1 (P = 0.14). l <sup>2</sup> = 53.2%					

Fig. 3 Comparison of overall survival (3A) and progression-free survival (3B) between bevacizumab-based regimen (experimental) and cetuximab-based regimen (control)

**Publisher's Note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.